CHAMPIONS ONCOLOGY INC
For the period ended Apr 30, 2024. Filed Jul 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jul 19, 2024
CSBR$4.75-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders' (Deficiency) Equity
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ (DEFICIENCY) EQUITY
(In Thousands except for shares)
| TotalStockholders'(Deficiency) Equity | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Treasury Stock · AdditionalPaid-inCapital · AccumulatedDeficit | |||||||
| Shares · Amount · Shares · Amount | |||||||
| Balance, April 30, 2022 | 13,522,441 | $14 | — | — | $81,064 | $(71,982) | $9,096 |
| Stock-based compensation expense | — | — | — | — | 864 | — | 864 |
| Issuance of common stock on exercise of stock options | 36,209 | — | — | — | 85 | — | 85 |
| Repurchase of common stock | — | — | 14,422 | (74) | — | — | (74) |
| Net loss | — | — | — | — | — | (5,335) | (5,335) |
| Balance, April 30, 2023 | 13,558,650 | $14 | 14,422 | $(74) | $82,013 | $(77,317) | $4,636 |
| Stock-based compensation expense | — | — | — | — | 1,118 | — | 1,118 |
| Issuance of common stock on exercise of stock options | 155,449 | — | — | — | 253 | — | 253 |
| Repurchase of common stock | — | — | 105,911 | (634) | — | — | (634) |
| Net loss | — | — | — | — | — | (7,276) | (7,276) |
| Balance, April 30, 2024 | 13,714,099 | $14 | 120,333 | $(708) | $83,384 | $(84,593) | $(1,903) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.